Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
Ocugen OCGN is pushing three eye gene therapy programs toward late-stage regulatory timelines, setting up a catalyst-heavy stretch in 2026 and 2027. That opportunity comes with familiar biotech trade-offs. The company has no approved products, spends heavily to move trials forward, and has leaned on capital …